Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olfr94 Inhibitors

Olfr94, a member of the olfactory receptor family 2 subfamily I in Mus musculus, plays a pivotal role in the olfactory system. This receptor, like other olfactory receptors, is integral to the process of odorant molecule detection and subsequent initiation of neuronal responses leading to smell perception. Structurally, Olfr94 is part of the G-protein-coupled receptor (GPCR) superfamily, characterized by a 7-transmembrane domain architecture. This structural feature is shared with a wide array of neurotransmitter and hormone receptors, underlining the receptor's versatility in signal transduction. Olfr94's function, governed by its interaction with specific odorant molecules, activates intracellular signaling pathways via G-protein activation. The olfactory receptor gene family, notably expansive in the genome, underpins the complexity and diversity of odorant recognition and signal processing. Inhibiting the function of Olfr94, or modulating its activity, presents a complex biochemical challenge due to the receptor's intricate nature and the diverse signaling pathways it engages. Inhibition can be direct, targeting the receptor itself, or indirect, influencing the receptor's activity through modulation of related pathways or cellular processes. The primary mechanism of direct inhibition could involve structural interference with the receptor's ligand-binding domain, preventing odorant molecule interaction and subsequent activation. This approach necessitates precise molecular targeting to ensure specificity and efficacy. Indirect inhibition, on the other hand, encompasses a broader spectrum of strategies. It can involve the modulation of downstream signaling pathways, alteration of membrane fluidity or receptor conformation, or interference with the receptor's post-translational modifications or trafficking. Each of these methods impacts the receptor's ability to transduce signals effectively, thus attenuating the olfactory response. GPCRs, including Olfr94, are subject to regulation by various cellular mechanisms, such as phosphorylation, interaction with regulatory proteins, and changes in membrane lipid composition. These processes are critical in determining the receptor's responsiveness and sensitivity. Chemical inhibitors that target these regulatory mechanisms can effectively modulate Olfr94's function. The chemicals listed above, while not exclusively designed for Olfr94 inhibition, provide insights into potential avenues for modulating its activity. They exemplify the diverse strategies employed in GPCR modulation, ranging from altering receptor conformation and membrane dynamics to influencing intracellular signaling cascades. In summary, the inhibition of Olfr94 requires a nuanced understanding of both the receptor's structural and functional characteristics and the intricate network of signaling pathways in which it operates. The strategies for inhibition, whether direct or indirect, must account for the receptor's role in the broader context of cellular and molecular olfaction processes. The exploration of these inhibitors not only sheds light on the potential modulation of olfactory receptors but also provides a window into the complex and dynamic world of GPCR-mediated signaling.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Sulconazole

61318-90-9sc-338599
100 mg
$1000.00
1
(0)

Sulconazole, an imidazole antifungal, inhibits cytochrome P450 enzymes, affecting steroid synthesis. This inhibition impacts GPCR function, including olfactory receptors like Olfr94, by altering membrane fluidity and receptor conformation.

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

Propranolol, a non-selective beta-adrenergic receptor antagonist, can influence GPCR-mediated pathways. This can lead to altered G-protein coupling efficiency in receptors like Olfr94, indirectly affecting their signaling.

Yohimbine hydrochloride

65-19-0sc-204412
sc-204412A
sc-204412B
1 g
5 g
25 g
$51.00
$171.00
$530.00
2
(1)

Yohimbine, an alpha-2 adrenergic receptor antagonist, can modulate GPCR-mediated signaling. Its antagonistic action can affect downstream GPCR pathways, potentially influencing the function of receptors like Olfr94.

Clozapine

5786-21-0sc-200402
sc-200402A
sc-200402B
sc-200402C
50 mg
500 mg
5 g
10 g
$69.00
$364.00
$2500.00
$4100.00
11
(1)

Clozapine, an atypical antipsychotic, acts on various neurotransmitter receptors, including GPCRs. Its broad receptor interaction profile can lead to modulation of GPCR pathways, indirectly affecting Olfr94 activity.

Ritanserin

87051-43-2sc-203681
sc-203681A
10 mg
50 mg
$89.00
$312.00
2
(1)

Ritanserin, a selective serotonin receptor antagonist, affects serotonin's modulation of GPCRs. This can lead to an indirect impact on the signaling of receptors like Olfr94 by altering the GPCR milieu.

Ondansetron

99614-02-5sc-201127
sc-201127A
10 mg
50 mg
$82.00
$333.00
1
(0)

Ondansetron, a serotonin 5-HT3 receptor antagonist, indirectly affects GPCR signaling pathways. Its action on serotonin receptors can influence the G-protein coupling in receptors like Olfr94, altering their signaling.

Metoprolol Tartrate

56392-17-7sc-205751
sc-205751A
5 g
25 g
$107.00
$243.00
3
(1)

Metoprolol, a beta-1 adrenergic receptor blocker, affects GPCR signaling indirectly. By blocking beta-1 receptors, it can alter G-protein coupling in related GPCRs, potentially impacting Olfr94 function.

Naloxone

465-65-6sc-477809
200 mg
$306.00
5
(0)

Naloxone, an opioid antagonist, influences GPCR signaling by blocking opioid receptors. This can lead to changes in GPCR-mediated signaling cascades, potentially affecting receptors like Olfr94.

Cimetidine

51481-61-9sc-202996
sc-202996A
5 g
10 g
$62.00
$86.00
1
(1)

Cimetidine, a histamine H2 receptor antagonist, can indirectly modulate GPCR activity. By inhibiting H2 receptors, it affects the histamine-mediated modulation of GPCRs, potentially influencing Olfr94 signaling.

Labetalol

36894-69-6sc-484723
50 mg
$180.00
(0)

Labetalol, a mixed alpha/beta adrenergic antagonist, modulates GPCR signaling pathways. Its action on both alpha and beta receptors can indirectly affect the signaling of GPCRs like Olfr94.